Table 3.
Effectiveness of Full and Half dose of ChAdOx1 nCoV-19 in the Viana population after adjusting for age and sex.
| Parameters | Full dose (n=6,402) | Half dose (n=16,570) | ||||
|---|---|---|---|---|---|---|
| All Cases | ||||||
| Age Groups | Cases/person-day | Incidence (per 1,000 person-year) |
1-RR (%) | Cases/person-day | Incidence (per 1,000 person-year) |
1-RR (%) |
| Males | ||||||
| 18–29 | 9/38,993 | 84.2 | 14.9 | 36/289,341 | 45.4 | 54.1 |
| 30–39 | 7/63,240 | 40.4 | 64.4 | 27/257,544 | 38.3 | 66.2 |
| 40–49 | 9/83,691 | 39.3 | 76.1 | 23/190,010 | 44.2 | 73.1 |
| All | 25/185,924 | 49.1 | 59.0 | 86/736,895 | 42.6 | 64.4 |
| Females | ||||||
| 18–29 | 7/59,916 | 42.6 | 65.5 | 36/296,591 | 44.3 | 64.1 |
| 30–39 | 14/93,381 | 54.7 | 69.9 | 34/232,206 | 53.4 | 70.6 |
| 40–49 | 18/124,078 | 53.0 | 74.2 | 20/153,036 | 47.7 | 76.7 |
| All | 39/277,375 | 51.3 | 68.8 | 90/681,833 | 48.2 | 70.7 |
| Cases Confirmed by RT-PCR | ||||||
| Age Groups | Cases/ person-day |
Incidence (per 1,000 person-year) |
Cases/ person-day |
Incidence (per 1,000 person-year) |
||
| Males | ||||||
| 18–29 | 3/38,993 | 28.1 | 18/289,341 | 22.7 | ||
| 30–39 | 3/63,240 | 17.3 | 14/257,544 | 19.8 | ||
| 40–49 | 3/83,691 | 13.1 | 11/190,010 | 21.1 | ||
| All | 9/185,924 | 17.7 | 43/736,895 | 21.3 | ||
| Females | ||||||
| 18–29 | 3/59,916 | 18.3 | 25/296,591 | 30.7 | ||
| 30–39 | 8/93,381 | 31.3 | 17/232,206 | 26.7 | ||
| 40–49 | 13/124,078 | 38.2 | 9/153,036 | 21.5 | ||
| All | 24/277,375 | 31.6 | 51/681,833 | 27.3 | ||
| Model-based Analysis Group oefficient |
-0.04 (-0.44 to 0.37) | |||||
CrI, Credibility Interval; Full dose, ChAdOx1 Full dose group; Half dose, ChAdOx1 Half dose group.